GST001: A Targeted Approach to Preterm Labor

GST001 is Gesthera’s lead development program for spontaneous preterm labor. It is described as a novel, orally available small molecule that selectively targets the prostaglandin F2α receptor. The development rationale is based on targeting inflammation and uterine contractions while aiming to reduce some of the fetal risks associated with non-specific prostaglandin inhibition. This selective mechanism […]